Related references
Note: Only part of the references are listed.Checkpoint kinase 1 inhibitors for potentiating systemic anticancer therapy
M. Maugeri-Sacca et al.
CANCER TREATMENT REVIEWS (2013)
Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
Judith E. Karp et al.
CLINICAL CANCER RESEARCH (2012)
P90 RSK arranges Chk1 in the nucleus for monitoring of genomic integrity during cell proliferation
Ping Li et al.
MOLECULAR BIOLOGY OF THE CELL (2012)
Checkpoint control and cancer
R. H. Medema et al.
ONCOGENE (2012)
Pushing the limits of targeted therapy in chronic myeloid leukaemia
Thomas O'Hare et al.
NATURE REVIEWS CANCER (2012)
c-Cbl and Cbl-b Ligases Mediate 17-Allylaminodemethoxygeldanamycin-induced Degradation of Autophosphorylated Flt3 Kinase with Internal Tandem Duplication through the Ubiquitin Proteasome Pathway
Gaku Oshikawa et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
Alfonso Quintas-Cardama et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
DNA Damage Stress and Inhibition of Jak2-V617F Cause Its Degradation and Synergistically Induce Apoptosis through Activation of GSK3β
Toshikage Nagao et al.
PLOS ONE (2011)
Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Michael S. Mathisen et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2011)
Status of PI3K inhibition and biomarker development in cancer therapeutics
B. Markman et al.
ANNALS OF ONCOLOGY (2010)
FLT3 as a therapeutic target in AML: still challenging after all these years
Thomas Kindler et al.
BLOOD (2010)
Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic
Paul Workman et al.
CANCER RESEARCH (2010)
Akt Activation Emulates Chk1 Inhibition and Bcl2 Overexpression and Abrogates G2 Cell Cycle Checkpoint by Inhibiting BRCA1 Foci
Ivana Tonic et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Akt/PKB suppresses DNA damage processing and checkpoint activation in late G2
Naihan Xu et al.
JOURNAL OF CELL BIOLOGY (2010)
Sorafenib Induces Apoptosis Specifically in Cells Expressing BCR/ABL by Inhibiting Its Kinase Activity to Activate the Intrinsic Mitochondrial Pathway
Tetsuya Kurosu et al.
CANCER RESEARCH (2009)
Structural and Functional Alterations of FLT3 in Acute Myeloid Leukemia
Soheil Meshinchi et al.
CLINICAL CANCER RESEARCH (2009)
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Florence I. Raynaud et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Phosphoinositide 3-kinase signaling overrides a G2 phase arrest checkpoint and promotes aberrant cell cycling and death of hematopoietic cells after DNA damage
Dipali Nimbalkar et al.
CELL CYCLE (2008)
The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor-/progesterone receptor-/HER-2-: Breast carcinomas
Lieve Verlinden et al.
CANCER RESEARCH (2007)
Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-δ
T. Kurosu et al.
ONCOGENE (2007)
Jak2: normal function and role in hematopoietic disorders
James N. Ihle et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2007)
The ability of sorafenib to inhibit oncogenic PDGFR beta and FLT3 mutants and overcome resistance to other small molecule inhibitors
Els Lierman et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2007)
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: A review of four phase I trials in patients with advanced refractory solid tumors
Dirk Strumberg et al.
ONCOLOGIST (2007)
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Ross L. Levine et al.
NATURE REVIEWS CANCER (2007)
Hematopoietic cytokines enhance Chk1-dependent G2/M checkpoint activation by etoposide through the Akt/GSK3 pathway to inhibit apoptosis
ZH Jin et al.
ONCOGENE (2005)
Lack of PTEN sequesters CHK1 and initiates genetic instability
J Puc et al.
CANCER CELL (2005)
The BCR-ABL story: Bench to bedside and back
S Wong et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Mechanisms of disease - Chronic myeloid leukemia - Advances in biology and new approaches to treatment
JM Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
5-aryl-pyrazolo[3,4-b]pyridazines:: Potent inhibitors of glycogen synthase kinase-3 (GSK-3)
J Witherington et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
FLT3 mutations in acute myeloid leukemia cell lines
H Quentmeier et al.
LEUKEMIA (2003)
Apoptosis: A link between cancer genetics and chemotherapy
RW Johnstone et al.
CELL (2002)
DNA damage-induced cell-cycle arrest of hematopoietic cells is overridden by activation of the PI-3 kinase/Akt signaling pathway
MK Henry et al.
BLOOD (2001)
Plat-E: an efficient and stable system for transient packaging of retroviruses
S Morita et al.
GENE THERAPY (2000)
The Akt-glycogen synthase kinase 3β pathway regulates transcription of atrial natriuretic factor induced by β-adrenergic receptor stimulation in cardiac myocytes
C Morisco et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
